U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
- Monday, September 28, 2020, 7:16
- Environment
- Add a comment
KING OF PRUSSIA, Pa., Sept. 28, 2020 /PRNewswire/ — CSL Behring, a global biotherapeutics leader, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for routine prophylaxis to…
About the Author
adminasapcorp has written 41279 stories on this site.